Search The Medical Knowledge Base

Drug Details

BACTROBAN NASAL

• Drug Class Description
  Broad spectrum antibiotics.
• Generic Name
  Mupirocin
• Presentation
  White soft paraffin based ointment containing a glycerin ester.
• Description
  Mupirocin 2.0% w/w as mupirocin calcium.
• Indications
  The elimination of nasal carriage of staphylococci, including methicillin resistant Staphylococcus aureus (MRSA).
• Adult Dosage
  

  Dosage: Adults (including the elderly) and children:

  Bactroban Nasal Ointment should be applied to the anterior nares two to three times a day as follows:

  A small amount of the ointment about the size of a match head is placed on the little finger and applied to the inside of each nostril. The nostrils are closed by pressing the sides of the nose together; this will spread the ointment throughout the nares. A cotton bud may be used instead of the little finger for the application in particular to infants or patients who are very ill.

  Nasal carriage should normally clear within 5-7 days of commencing treatment.

  Administration: Topical.

• Child Dosage
  As for adults.
• Contra Indications
  

  Bactroban Nasal Ointment should not be given to patients with a history of hypersensitivity to any of the constituents.

• Special Precautions
  

  As with all topical preparations care should be taken to avoid the eyes.

  In the rare event of a possible sensitisation reaction or severe local irritation occuring with the use of Bactroban Nasal Ointment, treatment should be discontinued, the product should be wiped off and appropriate alternative therapy for the infection instituted.

• Interactions
  

  The product is not known to interact with other medicaments.

• Adverse Drug Reactions
  

  Adverse reactions are listed below by system organ class and frequency. Frequencies are defined as : very common (1/10), common (1/100, <1/10), uncommon (1/1000, <1/100), rare (1/10,000, <1/1000), very rare (<1/10,000), including isolated reports. Uncommon adverse reactions were determined from pooled safety data from a clinical trial population of 422 treated patients encompassing 12 clinical studies. Very rare adverse reactions were primarily determined from post-marketing experience data and therefore refer to reporting rate rather than true frequency.

  Immune system disorders

  Very rare: Cutaneous hypersensitivity reactions.

  Respiratory, thoracic and mediastinal disorders

  Uncommon: Nasal mucosa reactions.